№ lp_1_2_53696
File format: docx
Character count: 8846
File size: 45 KB
This document is a formal request for a Type B meeting with the FDA to discuss preclinical, product, and clinical issues related to the development of Drug XY for the treatment of WZ Syndrome, focusing on study design and regulatory pathways.
Year:
20XX
Region / City:
Beltsville, MD
Subject:
Drug development
Document Type:
Meeting Request
Organization / Institution:
FDA
Author:
John Doe, MD
Target Audience:
FDA officials, drug development teams
Action Period:
Phase I
Approval Date:
Not specified
Date of Modification:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Document Type:
Regulatory submission packet
Target Audience:
FDA reviewers, clinical researchers
Scope:
Preclinical and clinical development planning
Therapeutic Area:
Pharmacology / Drug development
Contents:
Introduction, Clinical Background, Regulatory Background, Pharmacology, Clinical Plan, Toxicology, Chemistry, Manufacturing and Controls, Development Plans, FDA Questions, References
Year:
Not specified
Region / City:
Durham, NC
Theme:
Drug development, Pre-IND meeting
Document Type:
Meeting Package
Organization / Institution:
Duke University
Author:
Not specified
Target Audience:
FDA, Drug development team
Period of validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2023
Region / City:
Global
Topic:
Variable Frequency Drives
Document Type:
Technical Specification
Author:
Not specified
Target Audience:
Engineers, Technical Professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Standards:
UL 508C, CSA 22.2 No. 274-2017, UL 1995, CE mark 2006/42/EC, IEC 60529, EN 61800-3, IEEE C62.41
Quality Assurance:
In-circuit testing, computerized testing, MTBF 28 years
Description:
Technical specification document describing the mechanical and operational features of the HV600 Variable Frequency Drive (VFD) for industrial applications, with detailed information on performance, construction, standards, and protection mechanisms.
Year:
2024
Region / City:
Canberra, Australia
Topic:
Paediatric Diabetes Care
Document Type:
Clinical Guideline
Organization:
Canberra Health Services, Paediatric Endocrinology & Diabetes Service (PEDS)
Target Audience:
Paediatric endocrinologists, medical officers, ward nursing staff, diabetes educators
Age Group:
Children and adolescents 0–16 years
Scope:
Inpatient management of newly diagnosed Type 1 Diabetes Mellitus
Exclusions:
Diabetic Ketoacidosis management, Type 2 Diabetes, Cystic Fibrosis Related Diabetes, pre-existing T1DM, outpatient management
Year:
2018
Region / City:
London
Topic:
Diabulimia, Integrated Diabetes and Mental Health Pathway
Document Type:
Response Template
Organization:
NHS England
Author:
Not specified
Target Audience:
Health providers, commissioners
Period of Implementation:
15 months
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2020
Region / City:
Tallassee, AL
Topic:
Water Meter Specifications
Document Type:
Technical Specification
Organization:
Neptune Technology Group Inc.
Author:
Neptune Technology Group Inc.
Target Audience:
Utility Engineers, Procurement Managers
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Helsinki, Finland
Topic:
Biocides, Wood preservatives
Document type:
Repository document
Organization:
European Chemicals Agency
Author:
European Chemicals Agency
Target audience:
Stakeholders in biocides and wood preservation
Validity period:
Not specified
Approval date:
January 2026
Amendment date:
Not specified
Year:
Not specified
Region / city:
Not specified
Theme:
Gypsum board specifications
Document type:
Product specification
Organization / institution:
USG Corporation
Author:
Not specified
Target audience:
Architects, engineers, contractors, building professionals
Effective period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2026
Region / city:
Not specified
Topic:
Academic paper template
Document Type:
Template
Author:
Not specified
Target Audience:
Researchers, academics, authors submitting manuscripts
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
Imaginary Town
Topic:
Power Generation, Installation Documentation
Document Type:
Installation Form
Organization / Institution:
ABC electricity distribution DNO
Author:
N/A
Target Audience:
Generator and Installer
Period of Validity:
N/A
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2021
Region / City:
South Africa
Theme:
Occupational qualifications, skills programmes
Document Type:
Evaluation checklist
Organization / Institution:
Quality Council for Trades and Occupations (QCTO)
Author:
Not specified
Target Audience:
Quality partners, evaluators, QCTO officials
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Note:
Region / city
Topic:
Energy Storage Facilities
Document type:
Annex